GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Becton, Dickinson and Co (XSWX:BDX) » Definitions » Debt-to-EBITDA

Becton, Dickinson and Co (XSWX:BDX) Debt-to-EBITDA : 3.39 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Becton, Dickinson and Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Becton, Dickinson and Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was CHF1,791 Mil. Becton, Dickinson and Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was CHF14,213 Mil. Becton, Dickinson and Co's annualized EBITDA for the quarter that ended in Mar. 2024 was CHF4,724 Mil. Becton, Dickinson and Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 3.39.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Becton, Dickinson and Co's Debt-to-EBITDA or its related term are showing as below:

XSWX:BDX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.79   Med: 4.63   Max: 7.3
Current: 4.09

During the past 13 years, the highest Debt-to-EBITDA Ratio of Becton, Dickinson and Co was 7.30. The lowest was 1.79. And the median was 4.63.

XSWX:BDX's Debt-to-EBITDA is ranked worse than
81.16% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.245 vs XSWX:BDX: 4.09

Becton, Dickinson and Co Debt-to-EBITDA Historical Data

The historical data trend for Becton, Dickinson and Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Becton, Dickinson and Co Debt-to-EBITDA Chart

Becton, Dickinson and Co Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.77 5.87 4.01 3.64 3.61

Becton, Dickinson and Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.77 3.61 4.51 3.91 3.39

Competitive Comparison of Becton, Dickinson and Co's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Becton, Dickinson and Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Becton, Dickinson and Co's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Becton, Dickinson and Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Becton, Dickinson and Co's Debt-to-EBITDA falls into.



Becton, Dickinson and Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Becton, Dickinson and Co's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1026.444 + 13258.305) / 3960.039
=3.61

Becton, Dickinson and Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1791.418 + 14213.157) / 4723.796
=3.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Becton, Dickinson and Co  (XSWX:BDX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Becton, Dickinson and Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Becton, Dickinson and Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Becton, Dickinson and Co (XSWX:BDX) Business Description

Address
1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of estimated 2023 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.